The Bowman-Birk inhibitor (BBI) is a soybean-derived serine protease inhibitor with anti-inflammatory properties. Experimental autoimmune encephalomyelitis (EAE) serves as an animal model of the central nervous system (CNS) inflammatory disorder multiple sclerosis (MS). EAE is mediated by Th1 and Th17 cells which migrate into the CNS and initiate inflammation directed against myelin components, resulting in CNS pathology and neurological clinical deficit. We have shown previously that oral treatment with BBI delays onset of EAE and reduces its severity. These beneficial effects were associated with an increase in IL-10 secretion by immune cells of BBI-treated mice. It is not known, however, whether this was a causal relationship or simply an epiphenomenon. In the present study we provide evidence that BBI regulates CD4 + T cell immune responses in EAE. BBI administration delayed the onset of EAE and reduced its severity in an IL-10-dependent manner, as BBI-mediated suppression of EAE was abrogated in IL-10 knockout mice. The beneficial effects were accompanied by reduced IFN-γ, IL-17 and increased IL-10 production, as well as increased Foxp3 expression. CD4 + T cells were the major source of IL-10 in the periphery and in the CNS during BBI treatment. Furthermore, BBI-treated mice had reduced numbers of infiltrated cells in the CNS, including Th17 cells, as compared with PBS-treated control animals. In conclusion, our data provide clear evidence for the essential role of IL-10 in BBI-mediated suppression in EAE, and indicate that BBI may be a promising candidate for the development of a novel MS therapy.
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Introduction
Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS) characterized by progressive demyelination of the brain and spinal cord and accumulation of neurological deficit (Keegan and Noseworthy, 2002) . Experimental autoimmune encephalomyelitis (EAE) is an animal model of MS used to study its pathogenic mechanisms and test potential therapies (Cruz-Orengo et al., 2011) . In EAE, myelin-specific CD4 + T lymphocytes migrate into the CNS and mediate neuronal demyelination and damage, similar to that in MS patients (Axtell et al., 2010) . The Bowman-Birk inhibitor (BBI) is a soybean-derived protease inhibitor comprised of 71 amino acid residues, 7 disulfide bonds and with a molecular weight of 8 kDa. BBI can withstand boiling water temperature, is resistant to a wide pH range and proteolytic enzymes of the gastrointestinal tract; it is orally bioavailable, and nonallergenic (Park et al., 2007; Losso, 2008; Marin-Manzano et al., 2009) . BBI is functionally a double-headed serine protease inhibitor that inhibits both trypsin-and chymotrypsin-like proteases (Birk, 1985) . Thus far, several human serine proteases, associated with function of inflammatory cells, have been shown to be highly sensitive to inhibition by BBI, including elastase, alpha-chymotrypsin, chymase and cathepsin G (Larionova et al., 1993; Ware et al., 1997) . It is likely that there are additional, yet unknown, serine proteases susceptible to inhibition by BBI.
BBI is effective suppressor of carcinogenesis (Daly et al., 2006) , and has anti-inflammatory effects (Qi et al., 2005) . Our previous studies indicated that BBI reduces inflammation in EAE and attenuates neuronal loss, making it a potential candidate for oral therapy in MS (Touil et al., 2008) . However, the mechanism by which BBI ameliorates EAE is currently unclear.
IL-10 was first described as a factor produced by Th2 cells, which inhibits cytokine production by Th1 cells (Fiorentino et al., 1991) . It has been demonstrated that IL-10 inhibits the production of a wide range of T-cell cytokines by affecting antigen presentation and costimulation mediated by antigen-presenting cells (APCs) (de Waal Malefyt et al., 1991) . IL-10 also plays an important role in the regulation of autoimmune injury in EAE, as evidenced by increased susceptibility of IL-10 −/− mice to EAE (Bettelli et al., 1998) , whereas mice over-expressing IL-10 are highly resistant to EAE induction (Cua et al., 1999) . Also, further studies have shown that increased IL-10 levels in spinal cord correlate with EAE remission, and exogenous administration of IL-10 effectively ameliorated EAE when targeted directly to Journal of Neuroimmunology 245 (2012) 1-7
